{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:52:10Z","timestamp":1685076730599},"reference-count":45,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2021.13182","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T07:47:12Z","timestamp":1640591232000},"source":"Crossref","is-referenced-by-count":1,"title":["Establishment and characterization of NCC\u2011DMM1\u2011C1, a novel patient\u2011derived cell line of desmoplastic malignant pleural mesothelioma"],"prefix":"10.3892","volume":"23","author":[{"given":"Rei","family":"Noguchi","sequence":"first","affiliation":[{"name":"Division of Rare Cancer Research, National Cancer Center Research Institute, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yoshimatsu","sequence":"additional","affiliation":[{"name":"Division of Rare Cancer Research, National Cancer Center Research Institute, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Rare Cancer Research, National Cancer Center Research Institute, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akane","family":"Sei","sequence":"additional","affiliation":[{"name":"Division of Rare Cancer Research, National Cancer Center Research Institute, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Motoi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center Hospital, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center Hospital, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Rare Cancer Research, National Cancer Center Research Institute, Chuo\u2011ku, Tokyo 104\u20110045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"key20220302121724_b1-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/jcp.54.7.498","article-title":"Histological typing of lung and pleural tumours: Third edition","volume":"54","author":"Gibbs","year":"2001","journal-title":"J Clin Pathol"},{"key":"key20220302121724_b2-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization classification of tumors of the pleura: Advances since the 2004 classification","volume":"11","author":"Galateau-Salle","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20220302121724_b3-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12885-016-2745-8","article-title":"Malignant mesothelioma of the pleura with desmoplastic histology: A case series and literature review","volume":"16","author":"Hashimoto","year":"2016","journal-title":"BMC Cancer"},{"key":"key20220302121724_b4-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2214\/ajr.154.3.2106209","article-title":"CT in differential diagnosis of diffuse pleural disease","volume":"154","author":"Leung","year":"1990","journal-title":"AJR Am J Roentgenol"},{"key":"key20220302121724_b5-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2214\/ajr.155.5.2120965","article-title":"Malignant pleural mesothelioma: CT manifestations in 50 cases","volume":"155","author":"Kawashima","year":"1990","journal-title":"AJR Am J Roentgenol"},{"key":"key20220302121724_b6-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant pleural mesothelioma: Evaluation with CT, MR imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"Radiographics"},{"key":"key20220302121724_b7-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20220302121724_b8-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"key20220302121724_b9-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/CCO.0000000000000053","article-title":"Systemic treatment of malignant pleural mesothelioma: New agents in clinical trials raise hope of relevant improvements","volume":"26","author":"Christoph","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"key20220302121724_b10-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrc2820","article-title":"Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents","volume":"10","author":"Sharma","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20220302121724_b11-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"key20220302121724_b12-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"key20220302121724_b13-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1535-7163.MCT-15-0074","article-title":"Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression","volume":"14","author":"Teicher","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"key20220302121724_b14-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/carcin\/bgz066","article-title":"Whole-genome sequencing of human malignant mesothelioma tumours and cell lines","volume":"40","author":"Oey","year":"2019","journal-title":"Carcinogenesis"},{"key":"key20220302121724_b15-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"e58132","DOI":"10.1371\/journal.pone.0058132","article-title":"Phenotypes and karyotypes of human malignant mesothelioma cell lines","volume":"8","author":"Relan","year":"2013","journal-title":"PLoS One"},{"issue":"D1","key":"key20220302121724_b16-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"D1073","DOI":"10.1093\/nar\/gky984","article-title":"PDX Finder: A portal for patient-derived tumor xenograft model discovery","volume":"47","author":"Conte","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"key20220302121724_b17-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s13577-020-00382-2","article-title":"Establishment and characterization of NCC-CDS2-C1: A novel patient-derived cell line of CIC-DUX4 sarcoma","volume":"33","author":"Yoshimatsu","year":"2020","journal-title":"Hum Cell"},{"key":"key20220302121724_b18-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","article-title":"The cellosaurus, a cell-line knowledge resource","volume":"29","author":"Bairoch","year":"2018","journal-title":"J Biomol Tech"},{"key":"key20220302121724_b19-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ijc.27931","article-title":"Match criteria for human cell line authentication: Where do we draw the line?","volume":"132","author":"Capes-Davis","year":"2013","journal-title":"Int J Cancer"},{"key":"key20220302121724_b20-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s13577-020-00457-0","article-title":"Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma","volume":"34","author":"Noguchi","year":"2020","journal-title":"Hum Cell"},{"key":"key20220302121724_b21-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/biostatistics\/kxh008","article-title":"Circular binary segmentation for the analysis of array-based DNA copy number data","volume":"5","author":"Olshen","year":"2004","journal-title":"Biostatistics"},{"key":"key20220302121724_b22-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/bioinformatics\/btl646","article-title":"A faster circular binary segmentation algorithm for the analysis of array CGH data","volume":"23","author":"Venkatraman","year":"2007","journal-title":"Bioinformatics"},{"key":"key20220302121724_b23-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1093\/bioinformatics\/bti677","article-title":"A comparison study: Applying segmentation to array CGH data for downstream analyses","volume":"21","author":"Willenbrock","year":"2005","journal-title":"Bioinformatics"},{"key":"key20220302121724_b24-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"D652","DOI":"10.1093\/nar\/gkp995","article-title":"COSMIC (the catalogue of somatic mutations in cancer): A resource to investigate acquired mutations in human cancer","author":"Forbes","year":"2010","journal-title":"Nucleic Acids Res 38 (Database Issue)"},{"key":"key20220302121724_b25-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1128\/AAC.12.1.11","article-title":"Human interferon: Mass production in a newly established cell line, MG-63","volume":"12","author":"Billiau","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"key20220302121724_b26-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1158\/0008-5472.CAN-08-3660","article-title":"Kinome profiling in pediatric brain tumors as a new approach for target discovery","volume":"69","author":"Sikkema","year":"2009","journal-title":"Cancer Res"},{"key":"key20220302121724_b27-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"D512","DOI":"10.1093\/nar\/gku1267","article-title":"PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations","author":"Hornbeck","year":"2015","journal-title":"Nucleic Acids Res 43 (Database Issue)"},{"issue":"D1","key":"key20220302121724_b28-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"D506","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: A worldwide hub of protein knowledge","volume":"47","author":"UniProt","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"key20220302121724_b29-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"D767","DOI":"10.1093\/nar\/gkn892","article-title":"Human protein reference database-2009 update","author":"Keshava Prasad","year":"2009","journal-title":"Nucleic Acids Res 37 (Database Issue)"},{"key":"key20220302121724_b30-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S","article-title":"A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European organization for research and treatment of cancer lung cancer cooperative group","volume":"85","author":"van Meerbeeck","year":"1999","journal-title":"Cancer"},{"key":"key20220302121724_b31-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"key":"key20220302121724_b32-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Cancer"},{"key":"key20220302121724_b33-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"e65903","DOI":"10.1371\/journal.pone.0065903","article-title":"Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy","volume":"8","author":"Szulkin","year":"2013","journal-title":"PLoS One"},{"key":"key20220302121724_b34-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1016\/j.ejca.2013.05.008","article-title":"Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European organisation for research and treatment of cancer 08052)","volume":"49","author":"O'Brien","year":"2013","journal-title":"Eur J Cancer"},{"key":"key20220302121724_b35-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"Fennell","year":"2012","journal-title":"J Thorac Oncol"},{"key":"key20220302121724_b36-ol-23-02-13182","first-page":"841","article-title":"Cytotoxicity and sister chromatid exchanges induced in vitro by six anticancer drugs developed in the People's Republic of China","volume":"71","author":"Huang","year":"1983","journal-title":"J Natl Cancer Inst"},{"key":"key20220302121724_b37-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0.CO;2-V","article-title":"Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia","volume":"63","author":"Kantarjian","year":"1989","journal-title":"Cancer"},{"key":"key20220302121724_b38-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/cncr.22398","article-title":"Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy","volume":"109","author":"Quint\u00e1s-Cardama","year":"2007","journal-title":"Cancer"},{"key":"key20220302121724_b39-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"key20220302121724_b40-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","article-title":"Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion","volume":"6","author":"Tsao","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20220302121724_b41-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1535-7163.MCT-19-0724","article-title":"CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma","volume":"19","author":"Xu","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"key20220302121724_b42-ol-23-02-13182","first-page":"437","article-title":"Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme","volume":"46","author":"Dorai","year":"1994","journal-title":"Mol Pharmacol"},{"key":"key20220302121724_b43-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1432-1033.1992.tb17223.x","article-title":"Splicing of the platelet-derived-growth-factor A-chain mRNA in human malignant mesothelioma cell lines and regulation of its expression","volume":"208","author":"Langerak","year":"1992","journal-title":"Eur J Biochem"},{"key":"key20220302121724_b44-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"438","DOI":"10.18632\/genesandcancer.129","article-title":"Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines","volume":"8","author":"Melaiu","year":"2017","journal-title":"Genes Cancer"},{"key":"key20220302121724_b45-ol-23-02-13182","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T10:19:57Z","timestamp":1646216397000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2021.13182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,27]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,12,27]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2021.13182","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,27]]},"article-number":"64"}}